Drugs / AB821
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07027488 | Aug 2025 → Aug 2027 expected | melanoma | Yale University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-10-31 | Asher Biotherapeutics, Inc. | Results Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting asherbio.com ↗
The new preclinical data presented at SITC demonstrate that AB821 can improve the functionality of exhausted CD8+ T cells and promote their function and survival to effectively facilitate potent antitumor activity. |
| 2022-11-10 | Asher Biotherapeutics, Inc. | Results Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies asherbio.com ↗
AB821’s murine surrogate, muAB821, demonstrated potent single-dose monotherapy activity down to 0.1 mg/kg in MC38 colon cancer and T3 sarcoma tumor models, and showed synergistic anti-tumor activity with anti-PD1 therapy in multiple PD1-resistant tumor models. |
| 2022-04-08 | Asher Biotherapeutics, Inc. | Results Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting asherbio.com ↗
In addition, a single dose of murine CD8-IL21 surrogate demonstrated activity in multiple syngeneic tumor models without inducing body weight loss. |
| 2022-03-08 | Asher Biotherapeutics, Inc. | Results Asher Bio to Showcase Continued Progress with Lead Program AB248 and Growing Pipeline of Precisely-Targeted Immunotherapies at AACR Annual Meeting 2022 asherbio.com ↗
First preclinical data for AB821, a CD8-targeted IL-21, and CAR-T cell-targeted IL-2 demonstrate versatility and broad applicability of cis-targeting technology |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-31 | Asher Biotherapeutics, Inc. | Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting asherbio.com ↗ |
| 2022-11-10 | Asher Biotherapeutics, Inc. | Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies asherbio.com ↗ |
| 2022-10-05 | Asher Biotherapeutics, Inc. | Asher Bio to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies, AB248 and AB821, at SITC 2022 asherbio.com ↗ |
| 2022-04-08 | Asher Biotherapeutics, Inc. | Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting asherbio.com ↗ |
| 2022-03-08 | Asher Biotherapeutics, Inc. | Asher Bio to Showcase Continued Progress with Lead Program AB248 and Growing Pipeline of Precisely-Targeted Immunotherapies at AACR Annual Meeting 2022 asherbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07027488 ↗ |
| Route | Intravenous | “AB821 will be administered via IV infusion” NCT07027488 ↗ |